NEW YORK, Nov. 09, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the third quarter ended September 30, 2020 and recent company developments.
Read more:
TG Therapeutics Provides Business Update and Reports Third Quarter 2020 Financial Results
CHATHAM, N.J., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will be an invited speaker at the 3rd Annual Neuropsychiatric Drug Development Summit being held virtually November 10-12, 2020.
See more here:
Tonix Pharmaceuticals to Present at 3rd Annual Neuropsychiatric Drug Development Summit
Product revenue for the first nine months of 2020 increased 29% year-over-year to $30.8 million
More:
Fortress Biotech Reports Third Quarter 2020 Financial Results and Recent Corporate Highlights
CAMBRIDGE, Mass, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, its chief executive officer, and Robert Ross, M.D., its chief medical officer, will participate in a fireside chat at the upcoming Cowen 4th Annual IO Next Summit on Friday, November 13, 2020 at 10:45 a.m. ET. The discussion will focus on Surface’s lead programs, SRF617 (targeting CD39) and SRF388 (targeting IL-27).
Visit link:
Surface Oncology to Present at the Cowen IO Next Summit
SAN DIEGO, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the third quarter ended September 30, 2020 and provided a business update.
Read more:
Adamis Pharmaceuticals Announces Third Quarter 2020 Financial Results and Business Update
ROCKVILLE, MD, Nov. 09, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences in November and December:
Continued here:
MacroGenics to Participate in Upcoming Investor Conferences
- Firdapse® Third Quarter Net Revenues of $29.2 Million
See the original post:
Catalyst Pharmaceuticals Announces Third Quarter 2020 Financial Results and Provides Business Update
Company delivers strong results despite being adversely affected by California Wildfires
See the rest here:
Indus Holdings, Inc. Reports Record Third Quarter 2020 Results
ROCKVILLE, Md., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced regulatory updates for SPN-812 (viloxazine hydrochloride) for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age, and SPN-830 (apomorphine infusion pump) for the continuous treatment of motor fluctuations (“on-off” episodes) in Parkinson’s disease (PD).
Read more from the original source:
Supernus Provides Regulatory Updates for SPN-812 and SPN-830
Board Member Brian Shure will join executive team as Chief Financial OfficerSteve Neil will remain at the Company in a senior capacity
Read the rest here:
Indus Holdings, Inc. Announces New Chief Financial Officer